Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404764 | 1.00 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL12695816 | 1.00 | DRD2 (0.53) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL13505422 | 0.98 | DRD2 (0.51) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL83201 | 0.98 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL503006 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL134338 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL503067 | 0.83 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL18290968 | 0.82 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4249668 | 0.82 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4242930 | 0.82 | DRD2 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105793430-B | Process for the preparation of chiral 2-arylmorpholines | 豪夫迈·罗氏有限公司 | 2020-03-03 | — | — | CN | disclosed |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| CN-107903251-A | Pyrazole formylamine derivate as the TAAR conditioning agents for treating several conditions such as depression, diabetes and Parkinson's | 霍夫曼-拉罗奇有限公司 | 2018-04-13 | — | — | CN | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1805164-A2 | 6-(PYRIDINYL)-4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006036015-A2 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | DRD2 1604/4885DRD3 1330/4885 |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | TAAR1, TAAR5, TACR2 | DRD2 182/4885DRD3 323/4885 |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | TAAR1, TAAR5, TACR2 | DRD2 182/4885DRD3 323/4885 |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | DRD2 2732/4885DRD3 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.